Thousand Oaks-based Amgen beat analysts' expectations for the second quarter of 2022, with year-over-year growth in revenue and earnings per share. Amgen, one of the world’s largest biotech firms, announced the results after the markets closed on Aug. 4, and after it announced it will be acquiring ChemoCentryx, a California-based company, for $3.7 billion. Amgen…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
